What is ELND005?

ELND005 is scyllo-inositol, an oral inositol stereoisomer that is thought to neutralize toxic, low-N Aβ oligomers and prevent them from aggregating. Scyllo-inositol has been reported to lead to dose-dependent decreases in amyloid pathology, insoluble Aβ40 and Aβ42, and subsequent plaque accumulation in TgCRND8 mice.

What current research is being done to develop a cure for Down syndrome?

A. The study drug—called ELND005—is believed to have two potential benefits for people with Down syndrome: (1) prevent the accumulation of plaques that might contribute to Alzheimer’s disease, and (2) improve working memory and cognitive functioning by regulating myo-inositol levels in the brain.

What medication can help Down syndrome?

Naproxen (Aleve, Anaprox, Naprosyn, Naprelan)

Can u prevent Down syndrome?

Prevention. There’s no way to prevent Down syndrome. If you’re at high risk of having a child with Down syndrome or you already have one child with Down syndrome, you may want to consult a genetic counselor before becoming pregnant.

What are 3 interesting facts about Down syndrome?

Facts About Down Syndrome

• Down syndrome occurs in approximately one in 700 births.
• There are three types of Down syndrome.
• Down syndrome has been depicted in historical paintings from the 15th and 16th centuries.
• Prenatal screening for Down syndrome is available.
• Other health problems can occur with Down syndrome.

Which parent is responsible for Down syndrome?

To date, no behavioral activity of the parents or environmental factor is known to cause Down syndrome. After much research on these cell division errors, researchers know that: In the majority of cases, the extra copy of chromosome 21 comes from the mother in the egg.

What happened to ELND005?

In 2014, ELND005 reverted to Transition Therapeutics, which was acquired by Opko Health in 2016. ELND005 is scyllo-inositol, an oral inositol stereoisomer that is thought to neutralize toxic, low-N Aβ oligomers and prevent them from aggregating.

Is ELND005 effective for mild to moderate Alzheimer’s disease?

ELND005 in Patients With Mild to Moderate Alzheimer’s Disease. ELND005 may prevent or inhibit the build up of amyloid protein in the brains of AD patients. This is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study of oral ELND005 in male and female participants aged 50-85 years with mild to moderate AD.

How many patients were randomized to ELND005?

Methods: A total of 353 patients were randomized to ELND005 (250, 1,000, or 2,000 mg) or placebo twice daily for 78 weeks. Coprimary endpoints were the Neuropsychological Test Battery (NTB) and Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale.